Advertisement
| antibody engineering and therapeutics 2023: Antibody Engineering J. Donald Capra, 1997 The last decade has witnessed remarkable developments in antibody research and its therapeutic applications. With the methods of molecular biology it is now possible to manipulate the specificities and activities of antibody molecules to generate an almost limitless array of structures for both basic investigations and the clinical setting. The contributions to this volume cover all three domains of the antibody: the variable regions, the relatively neglected but crucial hinge, and the constant region. These studies provide critical structural and functional information about antibodies, while also pointing the way to the construction of molecules with enhanced or even novel properties. Bringing together major experts on antibody engineering, this book is highly recommended to faculty, postdoctoral fellows and graduate students in molecular biology, microbiology, immunology, cancer research and genetics. |
| antibody engineering and therapeutics 2023: Introduction to Antibody Engineering Florian Rüker, Gordana Wozniak-Knopp, 2021-01-04 This highly readable textbook serves as a concise and engaging primer to the emerging field of antibody engineering and its various applications. It introduces readers to the basic science and molecular structure of antibodies, and explores how to characterize and engineer them. Readers will find an overview of the latest methods in antibody identification, improvement and biochemical engineering. Furthermore, alternative antibody formats and bispecific antibodies are discussed. The book’s content is based on lectures for the specializations “Protein Engineering” and “Medical Biotechnology” within the Master’s curriculum in “Biotechnology.” The lectures have been held at the University of Natural Resources and Life Sciences, Vienna, in cooperation with the Medical University of Vienna, since 2012 and are continuously adapted to reflect the latest developments in the field. The book addresses Master’s and PhD students in biotechnology, molecular biology and immunology, and all those who are interested in antibody engineering. |
| antibody engineering and therapeutics 2023: Handbook of Therapeutic Antibodies Stefan Dübel, Janice M. Reichert, 2014-12-03 Dieses Nachschlagewerk zu therapeutischen Antikörpern sucht auch in der komplett überarbeiteten 2. Auflage seinesgleichen und bietet 30 % neue Inhalte zu Entwicklung, Herstellung und therapeutischen Anwendungen dieser Biomoleküle. |
| antibody engineering and therapeutics 2023: Antibodies and Their Role in Therapeutics Roohi Bansal, 2021-12-04 Beginning with the structure, types, functions, and gene organization of antibodies, the book aims to shine a detailed light on the monoclonal antibodies (often referred to as mAbs) that have revolutionized the fields of therapeutics and diagnostics. The book describes the different ways of generating chimeric, humanized, and fully human monoclonal antibodies, emphasizing phage display, hybridoma, and rDNA technology. In addition, the book focuses on the various recombinant antibody formats in detail: Drug conjugates: Antibody-drug conjugates (ADCs), Immunotoxins (Recombinant, Humanized and Fully Human) and Antibody-antibiotic conjugate (AAC) Bispecific antibodies: scFv based (BiTE, DARTs and TandAbs) and Full-length IgG based Abzymes and Antibody-directed enzyme prodrug therapy (ADEPT) Fc-fusion proteins Single-domain antibodies (VHH and IgNAR sdAb) The book discusses the various therapeutic applications of monoclonal antibodies, along with the immunogenicity issues. The book also covers the modes of administration and side effects of monoclonal antibodies, along with the challenges and issues faced while developing a monoclonal antibody into a therapeutic agent. Modifications introduced by the researchers to decrease the immunogenicity issues and increase the efficacy of therapeutic mAbs are also described. The book is an invaluable resource for researchers and students in biology and medicine, biotechnology, immunology, genetics, molecular biology, and anyone interested in antibody engineering. |
| antibody engineering and therapeutics 2023: Development of Antibody-Based Therapeutics Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, 2018-09-11 With a key focus on recent developments and advances in the field, this book provides in-depth coverage of topics fundamental to the development of targeted therapeutics. The expansion of targeted modalities in rapidly evolving therapeutic areas, such as immune-oncology, and developments with respect to combination therapies, novel technologies, and the therapeutic application of antibody-drug conjugates, are presented. Additionally, the book builds upon topics discussed in the first edition (2012) where recent innovations warrant elaboration. This, the second edition of Development of Antibody-Based Therapeutics: Translational Considerations, represents a comprehensive evaluation of progress in the field, which sits alongside the first edition to inform, in detail, professional and academic researchers, as well as graduate students. |
| antibody engineering and therapeutics 2023: Structure and Function of Antibodies Roy Jefferis, Koichi Kato, William R. (Bill) Strohl, 2021-02-05 This book provides a detailed description of all kinds of therapeutic antibodies including IgGs, IgAs, IgEs, and IgMs, bispecific antibodies, chimeric antigen receptor antibodies, and antibody fragments. Details about how each of these antibodies interact with their ligands, the immune system, and their targets are provided. Additionally, this book delves into the details of antibody, Fc, and variable chain structures, and how subtle changes in structure, charge, flexibility, post-translational modification, and the ability to bind to natural antibody ligands can result in a significant impact on antibody activity and functionality. Finally, the book explains the critical quality attributes of modern therapeutic antibodies and how to ensure that antibodies entering development have the best possible chance of success. |
| antibody engineering and therapeutics 2023: Monoclonal Antibody Production National Research Council, Institute for Laboratory Animal Research, Committee on Methods of Producing Monoclonal Antibodies, 1999-05-06 The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced. On March 26, 1998, AAVS submitted a second petition, stating that NIH failed to provide valid scientific reasons for not supporting a proposed ban. The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop. |
| antibody engineering and therapeutics 2023: Therapeutic Antibodies Yuti Chernajovsky, Ahuva Nissim, 2007-11-22 This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes. |
| antibody engineering and therapeutics 2023: Disease Control Priorities, Third Edition (Volume 6) King K. Holmes, Stefano Bertozzi, Barry R. Bloom, Prabhat Jha, 2017-11-06 Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings. |
| antibody engineering and therapeutics 2023: Cytotoxic Payloads for Antibody–Drug Conjugates David E Thurston, Paul J M Jackson, 2019-07-11 Antibody–drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (KadcylaTM), brentuximab vedotin (AdcetrisTM), inotuzumab ozogamicin (BesponsaTM), gemtuzumab ozogamicin (MylotargTM) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many. The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity. Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future. |
| antibody engineering and therapeutics 2023: Flow Cytometry Alice Longobardi Givan, 2013-04-10 Flow cytometry continually amazes scientists with its ever-expanding utility. Advances in flow cytometry have opened new directions in theoretical science, clinical diagnosis, and medical practice. The new edition of Flow Cytometry: First Principles provides a thorough update of this now classic text, reflecting innovations in the field while outlining the fundamental elements of instrumentation, sample preparation, and data analysis. Flow Cytometry: First Principles, Second Edition explains the basic principles of flow cytometry, surveying its primary scientific and clinical applications and highlighting state-of-the-art techniques at the frontiers of research. This edition contains extensive revisions of all chapters, including new discussions on fluorochrome and laser options for multicolor analysis, an additionalsection on apoptosis in the chapter on DNA, and new chapters onintracellular protein staining and cell sorting, including high-speed sorting and alternative sorting methods, as well as traditional technology. This essential resource: Assumes no prior knowledge of flow cytometry Progresses with an informal, engaging lecture style from simpleto more complex concepts Offers a clear introduction to new vocabulary, principles of instrumentation, and strategies for data analysis Emphasizes the theory relevant to all flow cytometry, with examples from a variety of clinical and scientific fields Flow Cytometry: First Principles, Second Edition provides scientists, clinicians, technologists, and students with the knowledge necessary for beginning the practice of flow cytometry and for understanding related literature. |
| antibody engineering and therapeutics 2023: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| antibody engineering and therapeutics 2023: Antibody Engineering Carl A. K. Borrebaeck, 1995 In presenting a practical overview of the engineering of recombinant human or mouse monoclonal antibodies, the book incisively addresses essential topics such as antibody structure relevant to engineering, recombinatorial cDNA libraries, phage display, synthetic and humanized antibodies, engineering of affinity and biological effector functions, and plant, mammalian, and bacterial expression vectors and hosts. Antibody Engineering, Second Edition - written by leading experts and now thoroughly updated - is a unique resource for current information on the subject. |
| antibody engineering and therapeutics 2023: Cell and Gene Therapies Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, 2018-11-27 In this book, experts in the field express their well-reasoned opinions on a range of complex, clinically relevant issues across the full spectrum of cell and gene therapies with the aim of providing trainee and practicing hematologists, including hematopoietic transplant physicians, with information that is relevant to clinical practice and ongoing research. Each chapter focuses on a particular topic, and the concise text is supported by numerous working tables, algorithms, and figures. Whenever appropriate, guidance is provided regarding the availability of potentially high-impact clinical trials. The rapid evolution of cell and gene therapies is giving rise to numerous controversies that need to be carefully addressed. In meeting this challenge, this book will appeal to all residents, fellows, and faculty members responsible for the care of hematopoietic cell transplant patients. It will also offer a robust, engaging tool to aid vital activities in the daily work of every hematology and oncology trainee. |
| antibody engineering and therapeutics 2023: Therapeutic Proteins Vladimir Voynov, Justin A. Caravella, 2016-05-01 Emphasizing the newest developments in the field, this volume presents detailed methodswith added emphasison therapeutic protein discovery. It features key tips and valuable implementation advice to ensure successful results. |
| antibody engineering and therapeutics 2023: Tietz Textbook of Laboratory Medicine - E-Book Nader Rifai, 2022-02-03 Use THE definitive reference for laboratory medicine and clinical pathology! Tietz Textbook of Laboratory Medicine, 7th Edition provides the guidance necessary to select, perform, and evaluate the results of new and established laboratory tests. Comprehensive coverage includes the latest advances in topics such as clinical chemistry, genetic metabolic disorders, molecular diagnostics, hematology and coagulation, clinical microbiology, transfusion medicine, and clinical immunology. From a team of expert contributors led by Nader Rifai, this reference includes access to wide-ranging online resources on Expert Consult — featuring the comprehensive product with fully searchable text, regular content updates, animations, podcasts, over 1300 clinical case studies, lecture series, and more. - Authoritative, current content helps you perform tests in a cost-effective, timely, and efficient manner; provides expertise in managing clinical laboratory needs; and shows how to be responsive to an ever-changing environment. - Current guidelines help you select, perform, and evaluate the results of new and established laboratory tests. - Expert, internationally recognized chapter authors present guidelines representing different practices and points of view. - Analytical criteria focus on the medical usefulness of laboratory procedures. - Use of standard and international units of measure makes this text appropriate for any user, anywhere in the world. - Elsevier eBooks+ provides the entire text as a fully searchable eBook, and includes animations, podcasts, more than 1300 clinical case studies, over 2500 multiple-choice questions, a lecture series, and more, all included with print purchase. - NEW! 19 additional chapters highlight various specialties throughout laboratory medicine. - NEW! Updated, peer-reviewed content provides the most current information possible. - NEW! The largest-ever compilation of clinical cases in laboratory medicine is included with print purchase on Elsevier eBooks+. - NEW! Over 100 adaptive learning courses included with print purchase on Elsevier eBooks+ offer the opportunity for personalized education. |
| antibody engineering and therapeutics 2023: Antibody Methods and Protocols Gabriele Proetzel, Hilmar Ebersbach, 2012-06-24 The rapidly growing field of antibody research is the result of many advancing technologies allowing current developments to take advantage of molecular engineering to create tailor-made antibodies. Antibody Methods and Protocols attempts to provide insight into the generation of antibodies using in vitro and in vivo approaches, as well as technical aspects for screening, analysis, and modification of antibodies and antibody fragments. The detailed volume is focused on basic protocols for isolating antibodies and, at the same time, it selects a range of specific areas with the aim of providing guides for the overall process of antibody isolation and characterization as well as protocols for enhancing classical antibodies and antibody fragments. Written in the highly successful Methods in Molecular BiologyTM series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and easy to use, Antibody Methods and Protocols provides a broad and useful background to support ongoing efforts by novices and experts alike and encourages the development of new imaginative approaches to this vital area of study. |
| antibody engineering and therapeutics 2023: Cell Culture Engineering Wei-Shu Hu, 2006-08-16 Since the introduction of recombinant human growth hormone and insulin a quarter century ago, protein therapeutics has greatly broadened the ho- zon of health care. Many patients suffering with life-threatening diseases or chronic dysfunctions, which were medically untreatable not long ago, can attest to the wonder these drugs have achieved. Although the ?rst generation of p- tein therapeutics was produced in recombinant Escherichia coli, most recent products use mammalian cells as production hosts. Not long after the ?rst p- duction of recombinant proteins in E. coli, it was realized that the complex tasks of most post-translational modi?cations on proteins could only be ef?ciently carried out in mammalian cells. In the 1990s, we witnessed a rapid expansion of mammalian-cell-derived protein therapeutics, chie?y antibodies. In fact, it has been nearly a decade since the market value of mammalian-cell-derived protein therapeutics surpassed that of those produced from E. coli. A common characteristic of recent antibody products is the relatively large dose required for effective therapy, demanding larger quantities for the treatment of a given disease. This, coupled with the broadening repertoire of protein drugs, has rapidly expanded the quantity needed for clinical applications. The increasing demand for protein therapeutics has not been met exclusively by construction of new manufacturing plants and increasing total volume capacity. More - portantly the productivity of cell culture processes has been driven upward by an order of magnitude in the past decade. |
| antibody engineering and therapeutics 2023: Nanobody Ulrich Rothbauer, Patrick Chames, 2021-03-30 Nanobodies have become outstanding tools for biomedical research, diagnostics and therapy. Recent advances in the identification and functionalization of target-specific nanobodies now make nanobody-based approaches broadly available to many researches in the field. This book provides a compilation of original research articles and comprehensive reviews covering important and up to date aspects of research on nanobodies and their applications for immunoassays, proteomics, protein crystallization and in vitro and in vivo imaging. |
| antibody engineering and therapeutics 2023: IgY-Technology: Production and Application of Egg Yolk Antibodies Xiao-Ying Zhang, Ricardo S. Vieira-Pires, Patricia M. Morgan, Rüdiger Schade, 2021-06-25 This first edited Volume on IgY-Technology, addresses the historical and dynamic development of IgY-applications. The authors cover the biological basis and theoretical context, methodological guidance, and applications of IgY-Technology. A focus is laid on the use of IgY-antibodies for prophylactic/therapeutic purposes in human and veterinary medicine. Aside from applications, the chapters also offer an evolutionary understanding of the IgY molecule, IgY receptors and practical prerequisites to produce IgY-antibodies. Guidance is given for every step of the process. Starting with an introduction to hens as a model species and including hen husbandry, hen egg-laying capacity and total IgY outcomes. Readers will also learn about immunization techniques, the advantages and limitations of different IgY extraction methods, as well as storage stability of the final product. The last part of the volume highlights hands-on aspects of applications, such as IgY delivery strategies, new methods to produce monoclonal IgY-antibodies or production of functional IgY fragments by phage-display as well as commercial exploitation of the technology. Thus, this book is a valuable resource and guide for Scientists, Clinicians and Health Product Developers in both human and veterinary medicine. |
| antibody engineering and therapeutics 2023: Digital Pathology Liron Pantanowitz, Anil V. Parwani, 2017 The definitive, complete reference of digital pathology! An extraordinarily comprehensive and complete book for individuals with anything from minimal knowledge to deep, accomplished experience in digital pathology. Easy to read and plainly written, Digital Pathology examines the history and technological evolution of digital pathology, from the birth of scanning technology and telepathology to three-dimensional imaging on large multi-touch displays and computer aided diagnosis. A must-have book for anyone wishing to learn more about and work in this exciting and critical information environment including pathologists, laboratory professionals, students and any other medical practitioners with a particular interest in the history and future of digital pathology. It can also be a useful reference for anyone, medical or non-medical, who have an interest in learning more about the field. Digital pathology is truly a game changer, and this book is a crucial tool for anyone wishing to know more. Subjects discussed in depth include: Static digital imaging; basics and clinical use. Digital imaging processes. Telepathology. While slide imaging. Clinical applications of whole slide imaging. Digital pathology for educational, quality improvement, research and other settings. Forensic digital imaging. |
| antibody engineering and therapeutics 2023: Antibody Fc Margaret Ackerman, Falk Nimmerjahn, 2013-08-06 Antibody Fc is the first single text to synthesize the literature on the mechanisms underlying the dramatic variability of antibodies to influence the immune response. The book demonstrates the importance of the Fc domain, including protective mechanisms, effector cell types, genetic data, and variability in Fc domain function. This volume is a critical single-source reference for researchers in vaccine discovery, immunologists, microbiologists, oncologists and protein engineers as well as graduate students in immunology and vaccinology. Antibodies represent the correlate of protection for numerous vaccines and are the most rapidly growing class of drugs, with applications ranging from cancer and infectious disease to autoimmunity. Researchers have long understood the variable domain of antibodies, which are responsible for antigen recognition, and can provide protection by blocking the function of their target antigen. However, recent developments in our understanding of the protection mediated by antibodies have highlighted the critical nature of the antibody constant, or Fc domain, in the biological activity of antibodies. The Fc domain allows antibodies to link the adaptive and innate immune systems, providing specificity to a wide range of innate effector cells. In addition, they provide a feedback loop to regulate the character of the immune response via interactions with B cells and antigen-presenting cells. - Clarifies the different mechanisms of IgG activity at the level of the different model systems used, including human genetic, mouse, and in vitro - Covers the role of antibodies in cancer, infectious disease, and autoimmunity and in the setting of monoclonal antibody therapy as well as naturally raised antibodies - Color illustrations enhance explanations of the immune system |
| antibody engineering and therapeutics 2023: Molecular Biology of the Cell , 2002 |
| antibody engineering and therapeutics 2023: Therapeutic Antibody Engineering William R Strohl, Lila M Strohl, 2012-10-16 The field of antibody engineering has become a vital and integral part of making new, improved next generation therapeutic monoclonal antibodies, of which there are currently more than 300 in clinical trials across several therapeutic areas. Therapeutic antibody engineering examines all aspects of engineering monoclonal antibodies and analyses the effect that various genetic engineering approaches will have on future candidates. Chapters in the first part of the book provide an introduction to monoclonal antibodies, their discovery and development and the fundamental technologies used in their production. Following chapters cover a number of specific issues relating to different aspects of antibody engineering, including variable chain engineering, targets and mechanisms of action, classes of antibody and the use of antibody fragments, among many other topics. The last part of the book examines development issues, the interaction of human IgGs with non-human systems, and cell line development, before a conclusion looking at future issues affecting the field of therapeutic antibody engineering. - Goes beyond the standard engineering issues covered by most books and delves into structure-function relationships - Integration of knowledge across all areas of antibody engineering, development, and marketing - Discusses how current and future genetic engineering of cell lines will pave the way for much higher productivity |
| antibody engineering and therapeutics 2023: Superstitions of the Irish Country People Padraic O'Farrell, 1978 |
| antibody engineering and therapeutics 2023: Antibody Drug Discovery Clive R. Wood, 2012 Antibody-based therapeutics are a central driver of the success of biopharmaceuticals. The discovery technology of this field is isolated to a limited number of centers of excellence in industry and academia. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field. Each chapter is written with a historical perspective that sets into context the significance of the key developments, and with the provision of “points to consider” for the reader as a value-added feature of the volume. All contributors are experts in their fields and have played pivotal roles in the creation of the technology. |
| antibody engineering and therapeutics 2023: Monoclonal Antibodies Vincent Ossipow, Nicolas Fischer, 2016-08-23 Monoclonal Antibodies: Methods and Protocols, Second Edition expands upon the previous edition with current, detailed modern approaches to isolate and characterize monoclonal antibodies against carefully selected epitopes. This edition includes new chapters covering the key steps to generate high quality monoclonals via different methods, from antigen generation to epitope mapping and quality control of the purified IgG. Chapters are divided into four parts corresponding to four distinct objectives. Part I covers monoclonal antibody generation, Part II deals with monoclonal antibody expression and purification, Part III presents methods for monoclonal antibody characterization and modification, and Part IV describes selected applications of monoclonal antibodies. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and practical, Monoclonal Antibodies: Methods and Protocols, Second Edition provides crucial initial steps of monoclonal antibody generation and characterization with state-of-the art protocols. |
| antibody engineering and therapeutics 2023: Antibody Engineering Volume 1 Roland E. Kontermann, Stefan Dübel, 2010-03-10 Antibodies are indispensable tools for research, diagnosis, and therapy. Recombinant approaches allow the modification and improvement of nearly all antibody properties, such as affinity, valency, specificity, stability, serum half-life, effector functions, and immunogenicity. Antibody Engineering provides a comprehensive toolbox covering the well-established basics but also many exciting new techniques. The protocols reflect the latest hands on knowledge of key laboratories in this still fast-moving field. Newcomers will benefit from the proven step-by-step protocols, which include helpful practical advice; experienced antibody engineers will appreciate the new ideas and approaches. The book is an invaluable resource for all those engaged in antibody research and development. |
| antibody engineering and therapeutics 2023: Monoclonal Antibody-Directed Therapy Veysel Kayser, Amita Datta-Mannan, 2022-01-28 The book deals with therapeutic monoclonal antibodies (mAbs) broadly, and relevant topics such as challenges and opportunities, next-generation antibody products, Antibody-Drug-Conjugates (ADC), bispecifics, glycosylation, and T-cell engagers are covered. Each topic has been written by leading groups around the world and the book should be of interest to researchers from both academia and industry. |
| antibody engineering and therapeutics 2023: Computational Structural Biology Torsten Schwede, 2008 This is a comprehensive introduction to Landau-Lifshitz equations and Landau-Lifshitz-Maxwell equations, beginning with the work by Yulin Zhou and Boling Guo in the early 1980s and including most of the work done by this Chinese group led by Zhou and Guo since. The book focuses on aspects such as the existence of weak solutions in multi dimensions, existence and uniqueness of smooth solutions in one dimension, relations with harmonic map heat flows, partial regularity and long time behaviors. The book is a valuable reference book for those who are interested in partial differential equations, geometric analysis and mathematical physics. It may also be used as an advanced textbook by graduate students in these fields. |
| antibody engineering and therapeutics 2023: Cell Culture Bioprocess Engineering, Second Edition Wei-Shou Hu, 2020-03-06 This book is the culmination of three decades of accumulated experience in teaching biotechnology professionals. It distills the fundamental principles and essential knowledge of cell culture processes from across many different disciplines and presents them in a series of easy-to-follow, comprehensive chapters. Practicality, including technological advances and best practices, is emphasized. This second edition consists of major updates to all relevant topics contained within this work. The previous edition has been successfully used in training courses on cell culture bioprocessing over the past seven years. The format of the book is well-suited to fast-paced learning, such as is found in the intensive short course, since the key take-home messages are prominently highlighted in panels. The book is also well-suited to act as a reference guide for experienced industrial practitioners of mammalian cell cultivation for the production of biologics. |
| antibody engineering and therapeutics 2023: DNA Cloning David M. Glover, 1985 V.1 - The use of phage lambda replacement vectors in the construction of representative genomic DNA libraries; Constructing and screening cDNA libraries in g10 and gt11; An alternative procedure for the synthesis of double-stranded cDNA for cloning in phage and plasmid vectors; Immunological detection of chimeric B-galactosidases expressed by plasmid vectors; The pEMBL family of single-stranded vectors; Techniques for transformation of E. coli; The use of genetic markers for the selection and allelic exchange of in vitro induced mutation that do not have a phenotype in E. coli; Tle oligonucleotide-directed construction of mutations in recombinant filamentous phage; broad host range cloning vectors for gram negative bacteria; v.2 - Bacillus cloning methods; gene cloning in streptomyces; Cloning in yeast; Genetic engineering of plants; P element mediated germ line transformation of drosophila; High efficiency gene transfer into mammalian cells; The construction and characterization of vaccina virus recombinants expressing foreign genes; Bovine papilloma virus DNA: a eukaryotic cloning vector. |
| antibody engineering and therapeutics 2023: The Critical Public Health Value of Vaccines National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Global Health, Forum on Microbial Threats, 2022-01-29 Immunization against disease is among the most successful global health efforts of the modern era, and substantial gains in vaccination coverage rates have been achieved worldwide. However, that progress has stagnated in recent years, leaving an estimated 20 million children worldwide either undervaccinated or completely unvaccinated. The determinants of vaccination uptake are complex, mutable, and context specific. A primary driver is vaccine hesitancy - defined as a delay in acceptance or refusal of vaccines despite availability of vaccination services. The majority of vaccine-hesitant people fall somewhere on a spectrum from vaccine acceptance to vaccine denial. Vaccine uptake is also hampered by socioeconomic or structural barriers to access. On August 17-20, 2020, the Forum on Microbial Threats at the National Academies of Sciences, Engineering, and Medicine held a 4-day virtual workshop titled The Critical Public Health Value of Vaccines: Tackling Issues of Access and Hesitancy. The workshop focused on two main areas (vaccine access and vaccine confidence) and gave particular consideration to health systems, research opportunities, communication strategies, and policies that could be considered to address access, perception, attitudes, and behaviors toward vaccination. This publication summarizes the presentations and discussion of the workshop. |
| antibody engineering and therapeutics 2023: Herbal Medicine Iris F. F. Benzie, Sissi Wachtel-Galor, 2011-03-28 The global popularity of herbal supplements and the promise they hold in treating various disease states has caused an unprecedented interest in understanding the molecular basis of the biological activity of traditional remedies. Herbal Medicine: Biomolecular and Clinical Aspects focuses on presenting current scientific evidence of biomolecular ef |
| antibody engineering and therapeutics 2023: Cancer and IgE Manuel L. Penichet, Erika Jensen-Jarolim, 2010-01-23 Erika Jensen-Jarolim and Manuel L. Penichet 1. 1 Background Infectious diseases, being the major burden in the history of mankind worldwide th until the beginning of the 20 century, were important triggers in the understanding of immunological mechanisms. In contrast to infectious diseases, reports of all- gies and cancers were less common, but increased tremendously within the last century. Based on the US mortality data of the National Center for Health Statistics, Centers for Disease Control and Prevention 2009, a recent report from the American Cancer Society indicated that the number of cancer deaths increased approximately from 100,000 to 550,000 per year between 1930 and 2006, paralleling the increase of the total population during this period. Leading causes of death from cancer are lung and bronchus cancer, in men prostate cancer, and in women breast c- cer [1, 2]. Normalization to population size shows that the cancer death rate for most malignancies has been generally stable, although the mortality rate of certain malignancies, such as lung and bronchus cancer, has increased over the last 50 years [1-3]. In allergy, the situation is less clear, because for the time period around the turn of th the 19 century, only imprecise information is available. However, within the last 30 years the incidences of allergies has doubled not only in industrial countries, but in developing countries as well [4]. |
| antibody engineering and therapeutics 2023: FDA's Drug Review Process and the Package Label Tom Brody, 2017-12-01 FDA's Drug Review Process and the Package Label provides guidance to pharmaceutical companies for writing FDA-submissions, such as the NDA, BLA, Clinical Study Reports, and Investigator's Brochures. The book provides guidance to medical writers for drafting FDA-submissions in a way more likely to persuade FDA reviewers to grant approval of the drug. In detail, the book reproduces data on efficacy and safety from one hundred different FDA-submissions (NDAs, BLAs). The book reproduces comments and complaints from FDA reviewers regarding data that are fragmentary, ambiguous, or that detract from the drug's approvability, and the book reveals how sponsors overcame FDA's concerns and how sponsors succeeded in persuading FDA to grant approval of the drug. The book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely text and data from NDAs and BLAs, as published on FDA's website. The source material for writing this book included about 80,000 pages from FDA's Medical Reviews, FDA's Clinical Pharmacology Reviews, and FDA's Pharmacology Reviews, from one hundred different NDAs or BLAs for one hundred different drugs. Each chapter focuses on a different section of the package label, e.g., the Dosage and Administration section or the Drug Interactions section, and demonstrates how the sponsor's data supported that section of the package label. - Reveals strategies for winning FDA approval and for drafting the package label - Examples are from one hundred FDA-submissions (NDAs, BLAs) for one hundred different drugs, e.g., for oncology, metabolic diseases, autoimmune diseases, and neurological diseases - This book uses the most reliable and comprehensive source of information available for writing FDA-submissions, namely, the data from NDAs and BLAs as published on FDA's website at the time FDA grants approval to the drug |
| antibody engineering and therapeutics 2023: Current Trends in Monoclonal Antibody Development and Manufacturing Steven J. Shire, Wayne Gombotz, Karoline Bechtold-Peters, James Andya, 2009-11-11 Monoclonal antibodies represent one of the fastest growing areas of new drug development within the pharmaceutical industry. Several blockbuster products have been approved over the past several years including Rituxan, Remicade, Avastin, Humira, and Herceptin. In addition, over 300 new drugs are currently in clinical trials. With both large, established biotechnology companies and small start-ups involved in the development of this important class of molecules, monoclonal antibodies products will become increasingly prevalent over the next decade. Recently the regulatory review of monoclonal antibodies has been moved from Center for Biologics and Research to the Center for Drug Evaluation and Research (CDER) division of the US Food and Drug Administration. It is anticipated that CDER will expect a certain minimal amount of data to be provided as more of these products move through the regulatory pipeline. Current Trends in Monoclonal Antibody Development and Manufacturing will provide readers with an understanding of what is currently being done in the industry to develop, manufacture, and release monoclonal antibody products and what will be required for a successful regulatory submission. |
| antibody engineering and therapeutics 2023: A Crack In Creation Jennifer A. Doudna, Samuel H. Sternberg, 2017-06-13 BY THE WINNER OF THE 2020 NOBEL PRIZE IN CHEMISTRY | Finalist for the Los Angeles Times Book Prize “A powerful mix of science and ethics . . . This book is required reading for every concerned citizen—the material it covers should be discussed in schools, colleges, and universities throughout the country.”— New York Review of Books Not since the atomic bomb has a technology so alarmed its inventors that they warned the world about its use. That is, until 2015, when biologist Jennifer Doudna called for a worldwide moratorium on the use of the gene-editing tool CRISPR—a revolutionary new technology that she helped create—to make heritable changes in human embryos. The cheapest, simplest, most effective way of manipulating DNA ever known, CRISPR may well give us the cure to HIV, genetic diseases, and some cancers. Yet even the tiniest changes to DNA could have myriad, unforeseeable consequences, to say nothing of the ethical and societal repercussions of intentionally mutating embryos to create “better” humans. Writing with fellow researcher Sam Sternberg, Doudna—who has since won the Nobel Prize for her CRISPR research—shares the thrilling story of her discovery and describes the enormous responsibility that comes with the power to rewrite the code of life. “The future is in our hands as never before, and this book explains the stakes like no other.” — George Lucas “An invaluable account . . . We owe Doudna several times over.” — Guardian |
| antibody engineering and therapeutics 2023: Antibody Engineering Damien Nevoltris, Patrick Chames, 2019-12-10 This detailed new edition provides complete and easy access to a variety of antibody engineering techniques. The volume explores topics such as the generation of native, synthetic, or immune antibody libraries, the selection of lead candidates via the different powerful and innovative display technologies, Fc engineering, as well as their production, characterization, and optimization of antibodies. Written for the highly successful Methods in Molecular Biology series, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and up-to-date, Antibody Engineering: Methods and Protocols, Third Edition presents the reader with an extensive toolbox to create the powerful molecules of tomorrow. |
| antibody engineering and therapeutics 2023: State-Of-the-Art and Emerging Technologies for Therapeutic Monoclonal Antibody Characterization Volume 2. Biopharmaceutical Characterization John E. Schiel, Darryl L. Davis, Oleg V. Borisov, Oleg Borisov, 2016-06-24 Distributed in print by Oxford University Press. |
Antibody - Wikipedia
Each antibody binds to a specific antigen in a highly specific interaction analogous to a lock and key. An antibody (Ab) or immunoglobulin (Ig) is a large, Y-shaped protein belonging to the …
Antibodies: Definition, Types & Function - Cleveland Clinic
May 6, 2022 · An antibody is a protein produced by your immune system to attack and fight off these antigens. How do antibodies fight off antigens? The molecules on the surfaces of …
Antibody | Definition, Structure, Function, & Types | Britannica
May 30, 2025 · Antibody, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto …
Antibody: Definition, Structure, Types, Forms, Functions
Aug 3, 2023 · Antibody (Immunoglobulin) diversity. The immune system has the ability to generate a high level of diversity in order to recognize a very vast range of unique molecules estimated …
What is an antibody? - Medical News Today
Aug 11, 2021 · Antibodies develop in response to an infection or enter the body passively through vaccination. An antibody is sometimes called an immunoglobulin. But not all antibodies are …
Physiology, Antibody - StatPearls - NCBI Bookshelf
May 1, 2023 · The five antibody classes produced by the body include IgG, IgM, IgA, IgD, and IgE. IgM is the first antibody produced and acts as a B-cell surface immunoglobulin(Ig). …
Antibodies: Definition, Types, and Function - Health
Sep 8, 2024 · IgG: The most abundant antibody found in the body. It can help to block infections caused by bacteria, viruses, parasites , or other disease-causing organisms.
Antibody - National Human Genome Research Institute
6 days ago · An antibody is a protein component of the immune system that circulates in the blood, recognizes foreign substances like bacteria and viruses, and neutralizes them.
Antibody basics - Abcam
The basic principle of any immunoassay is that a specific antibody binds with its specific antigen, forming an exclusive antibody-antigen complex. This chapter defines what an antigen is and …
Antibody- Structure, Classes and Functions
Jan 23, 2024 · Antibody (Ab) also know as Immunoglobulin (Ig) is the large Y shaped protein produced by the body’s immune system when it detects harmful substances, called antigens …
Antibody - Wikipedia
Each antibody binds to a specific antigen in a highly specific interaction analogous to a lock and key. An antibody (Ab) or immunoglobulin (Ig) is a large, Y-shaped protein belonging to the …
Antibodies: Definition, Types & Function - Cleveland Clinic
May 6, 2022 · An antibody is a protein produced by your immune system to attack and fight off these antigens. How do antibodies fight off antigens? The molecules on the surfaces of …
Antibody | Definition, Structure, Function, & Types | Britannica
May 30, 2025 · Antibody, a protective protein produced by the immune system in response to the presence of a foreign substance, called an antigen. Antibodies recognize and latch onto …
Antibody: Definition, Structure, Types, Forms, Functions
Aug 3, 2023 · Antibody (Immunoglobulin) diversity. The immune system has the ability to generate a high level of diversity in order to recognize a very vast range of unique molecules estimated …
What is an antibody? - Medical News Today
Aug 11, 2021 · Antibodies develop in response to an infection or enter the body passively through vaccination. An antibody is sometimes called an immunoglobulin. But not all antibodies are …
Physiology, Antibody - StatPearls - NCBI Bookshelf
May 1, 2023 · The five antibody classes produced by the body include IgG, IgM, IgA, IgD, and IgE. IgM is the first antibody produced and acts as a B-cell surface immunoglobulin(Ig). …
Antibodies: Definition, Types, and Function - Health
Sep 8, 2024 · IgG: The most abundant antibody found in the body. It can help to block infections caused by bacteria, viruses, parasites , or other disease-causing organisms.
Antibody - National Human Genome Research Institute
6 days ago · An antibody is a protein component of the immune system that circulates in the blood, recognizes foreign substances like bacteria and viruses, and neutralizes them.
Antibody basics - Abcam
The basic principle of any immunoassay is that a specific antibody binds with its specific antigen, forming an exclusive antibody-antigen complex. This chapter defines what an antigen is and …
Antibody- Structure, Classes and Functions - MicrobiologyInfo.com
Jan 23, 2024 · Antibody (Ab) also know as Immunoglobulin (Ig) is the large Y shaped protein produced by the body’s immune system when it detects harmful substances, called antigens …
